miR-1187 induces podocyte injury and diabetic nephropathy through autophagy

Bin Chen1,2, Qiang He1,3

  • 1Medical College of Soochow University, Suzhou, China.

Insights

MicroRNA-1187 (miR-1187) is elevated in diabetic nephropathy (DN) and promotes podocyte injury by inhibiting autophagy. Inhibiting miR-1187 may offer a new therapeutic strategy for DN.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Endocrinology

Background:

  • Diabetic nephropathy (DN) is a major complication of diabetes, characterized by podocyte injury.
  • MicroRNAs (miRNAs) are implicated in the pathogenesis of DN.
  • The specific role of miR-1187 in DN and podocyte injury requires further investigation.

Purpose of the Study:

  • To investigate the role and regulatory mechanism of miR-1187 in the development of DN and podocyte injury.
  • To explore miR-1187 as a potential therapeutic target for DN.

Main Methods:

  • Assessed miR-1187 expression in podocytes under high glucose (HG) conditions and in a mouse model of DN (db/db mice).
  • Administered miR-1187 inhibitors to HG-treated podocytes and db/db mice.
  • Evaluated podocyte apoptosis, renal function, proteinuria, and glomerular apoptosis.
  • Investigated the effect of miR-1187 on autophagy levels and flux in podocytes and glomeruli.

Main Results:

  • miR-1187 expression was upregulated in podocytes exposed to HG and in the kidneys of db/db mice.
  • Inhibition of miR-1187 reduced HG-induced podocyte apoptosis, improved renal function, decreased proteinuria, and attenuated glomerular apoptosis in db/db mice.
  • miR-1187 was found to inhibit autophagy in HG-exposed podocytes and glomeruli of DN mice.
  • miR-1187 inhibition reversed HG-induced podocyte injury and autophagy flux inhibition.

Conclusions:

  • miR-1187 plays a critical role in promoting podocyte injury and DN progression, partly by inhibiting autophagy.
  • Targeting miR-1187 presents a potential therapeutic strategy for mitigating high glucose-induced podocyte damage and DN progression.

Related Concept Videos

Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
4.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Delivery Pathways to the Lysosome01:36

Delivery Pathways to the Lysosome

Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
6.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.7K